ImmunityBio Stock Forecast, Price & News

+0.12 (+0.70 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $17.38
50-Day Range N/A
52-Week Range
Now: $17.38
Volume888,780 shs
Average Volume1.51 million shs
Market Capitalization$1.90 billion
P/E RatioN/A
Dividend YieldN/A
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, macrophage polarizing peptides, bi-specific fusion proteins targeting TGFb and IL-12, adenovirus, and yeast vaccine therapies targeting tumor-associated antigens and neoepitopes. ImmunityBio, Inc. was formerly known as NantCell, Inc. and changed its name to ImmunityBio, Inc. in June 2019. The company was incorporated in 2014 and is based in El Segundo, California. ImmunityBio, Inc. operates as a subsidiary of NantWorks, LLC.

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:IBRX
Phone310 883 1300
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$1.90 billion
Next Earnings Date5/10/2021 (Estimated)


ImmunityBio (NASDAQ:IBRX) Shares Gap Up to $16.76
April 14, 2021 |
ImmunityBio (NASDAQ:IBRX) Trading 6.3% Higher
April 13, 2021 |
ImmunityBio is Now Oversold (IBRX)
April 9, 2021 |
ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $18.69
April 9, 2021 |
ImmunityBio (NASDAQ:IBRX) Shares Gap Up After Analyst Upgrade
April 8, 2021 |
ImmunityBio (NASDAQ:IBRX) Shares Down 5%
April 6, 2021 |
ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $23.74
April 1, 2021 |
ImmunityBio (NASDAQ:IBRX) Stock Price Down 4.9%
March 30, 2021 |
ImmunityBio, Inc. (IBRX)
March 29, 2021 |
ImmunityBio (NASDAQ:IBRX) Shares Gap Down to $30.89
March 26, 2021 |
See More Headlines


Overall MarketRank

1.70 out of 5 stars

Medical Sector

250th out of 2,025 stocks

Biotechnology Industry

20th out of 148 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.12 (+0.70 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IBRX News and Ratings via Email

Sign-up to receive the latest news and ratings for IBRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

ImmunityBio (NASDAQ:IBRX) Frequently Asked Questions

Is ImmunityBio a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ImmunityBio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ImmunityBio stock.
View analyst ratings for ImmunityBio
or view top-rated stocks.

What stocks does MarketBeat like better than ImmunityBio?

Wall Street analysts have given ImmunityBio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but ImmunityBio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is ImmunityBio's next earnings date?

ImmunityBio is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for ImmunityBio

What price target have analysts set for IBRX?

1 analysts have issued twelve-month price targets for ImmunityBio's shares. Their forecasts range from $25.00 to $25.00. On average, they anticipate ImmunityBio's share price to reach $25.00 in the next twelve months. This suggests a possible upside of 43.8% from the stock's current price.
View analysts' price targets for ImmunityBio
or view top-rated stocks among Wall Street analysts.

Who are ImmunityBio's key executives?

ImmunityBio's management team includes the following people:
  • Dr. Patrick Soon-Shiong F.A.C.S., M.Sc., FRCS (C), M.D., FACS, Exec. Chairman (Age 68, Pay $362.63k)
  • Mr. David Sachs, Chief Financial Officer (Age 43, Pay $567.4k)
  • Mr. Richard Gerald Adcock, Chief Exec. Officer (Age 52)
  • Dr. Leonard S. Sender, Chief Operating Officer
  • Ms. Sarah Singleton, Chief Communications Officer
  • Dr. Fabio M. Benedetti, Chief Strategy Officer (Age 55)
  • Dr. Sandeep K. Reddy, Chief Medical Officer
  • Mr. Shahrooz Rabizadeh, Chief Science Officer of Fusion Proteins & Neoepitope
  • Dr. Kayvan Niazi Ph.D., Chief Science Officer of Immunology & Vaccinology
  • Dr. Barry J. Simon, Chief Corp. Affairs Officer (Age 56)

Who are some of ImmunityBio's key competitors?

What is ImmunityBio's stock symbol?

ImmunityBio trades on the NASDAQ under the ticker symbol "IBRX."

Who are ImmunityBio's major shareholders?

ImmunityBio's stock is owned by a number of institutional and retail investors. Top institutional shareholders include West Oak Capital LLC (0.00%).

Which major investors are buying ImmunityBio stock?

IBRX stock was purchased by a variety of institutional investors in the last quarter, including West Oak Capital LLC.

How do I buy shares of ImmunityBio?

Shares of IBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ImmunityBio's stock price today?

One share of IBRX stock can currently be purchased for approximately $17.38.

How much money does ImmunityBio make?

ImmunityBio has a market capitalization of $1.90 billion.

What is ImmunityBio's official website?

The official website for ImmunityBio is

How can I contact ImmunityBio?

The company can be reached via phone at 310 883 1300.

This page was last updated on 4/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.